Chan School of Public Health have now found that medications such as GLP-1 receptor agonists do not increase congenital malformation risk in pregnancy when compared to insulin therapy
It might be safe to use GLP-1 [receptor agonists] in the preoperative period, Qais AbuHasan , MD, research fellow at the Indiana University School of Medicine, who presented the findings, said in the release
Short-Acting vs Long-Acting Formulations Short-acting GLP-1 medications have shorter half-lives and more frequent dosing: Exenatide immediate-release (Byetta) Half-life of approximately 24 hours, administered twice daily Lixisenatide (Lyxumia) Half-life of approximately 3 hours, administered once daily Long-acting formulations demonstrate markedly different pharmacokinetics: Semaglutide Half-life of approximately 7 days (168 hours), administered weekly Dulaglutide Half-life of approximately 5 days (120 hours), administered weekly Liraglutide Half-life of approximately 13 hours, administered daily Exenatide extended-release Half-life of approximately 2 weeks, administered weekly Clearance Pathways GLP-1 medications are eliminated from the body through different pathways depending on the specific agent: Exenatide and lixisenatide are primarily eliminated through the kidneys
Any history of tumors or cancer requires serious medical caution
